Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Avivit Peer

Showing results (31-40 of 49) with videos related to

Pageof 5
Sort By:
BMC Cancer|July 25, 2024
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab for advanced urothelial carcinoma: results from the randomized phase III ECHO-303/KEYNOTE-698 studyIrfan Cicin, Elizabeth R Plimack, Howard Gurney, et al.
Future Oncology (London, England)|February 24, 2026
Steroidogenesis inhibitor opevesostat (MK-5684) for metastatic castration-resistant prostate cancer: OMAHA-003 and OMAHA-004 trial designsEvan Y Yu, Christian Gratzke, Mauricio Burotto, et al.
The Oncologist|July 7, 2016
Outcome of Patients With Metastatic Chromophobe Renal Cell Carcinoma Treated With SunitinibDaniel Keizman, David Sarid, Jae L Lee, et al.
The Prostate|August 24, 2019
Re-treatment with radium-223: 2-year follow-up from an international, open-label, phase 1/2 study in patients with castration-resistant prostate cancer and bone metastasesOliver Sartor, Daniel Heinrich, Neil Mariados, et al.
The Oncologist|December 7, 2013
Active smoking may negatively affect response rate, progression-free survival, and overall survival of patients with metastatic renal cell carcinoma treated with sunitinibDaniel Keizman, Maya Gottfried, Maya Ish-Shalom, et al.
Nature Medicine|June 1, 2024
Pembrolizumab for advanced urothelial carcinoma: exploratory ctDNA biomarker analyses of the KEYNOTE-361 phase 3 trialThomas Powles, Yen-Hwa Chang, Yoshiaki Yamamoto, et al.
BMC Cancer|July 25, 2024
Pembrolizumab plus either epacadostat or placebo for cisplatin-ineligible urothelial carcinoma: results from the ECHO-307/KEYNOTE-672 studyAndrea Necchi, Michiel S Van der Heijden, Dmytro Trukhin, et al.
Frontiers in Oncology|June 9, 2023
Erdafitinib treatment in metastatic urothelial carcinoma: a real-world analysisKeren Rouvinov, Eran Levanon, Avivit Peer, et al.
Nature Medicine|August 7, 2025
Adjuvant nivolumab in muscle-invasive urothelial carcinoma: exploratory biomarker analysis of the randomized phase 3 CheckMate 274 trialMatthew D Galsky, Dean F Bajorin, Yoshihiko Tomita, et al.
Urologic Oncology|October 30, 2024
Bempegaldesleukin plus nivolumab in first-line advanced/metastatic urothelial carcinoma: Results from a phase II single-arm study (PIVOT-10)Arlene O Siefker-Radtke, Robert A Huddart, Mehmet A Bilen, et al.
Pageof 5

Showing results (31-40 of 49) with videos related to

Sort By:
Pageof 5
BMC Cancer|July 25, 2024
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab for advanced urothelial carcinoma: results from the randomized phase III ECHO-303/KEYNOTE-698 studyIrfan Cicin, Elizabeth R Plimack, Howard Gurney, et al.
Future Oncology (London, England)|February 24, 2026
Steroidogenesis inhibitor opevesostat (MK-5684) for metastatic castration-resistant prostate cancer: OMAHA-003 and OMAHA-004 trial designsEvan Y Yu, Christian Gratzke, Mauricio Burotto, et al.
The Oncologist|July 7, 2016
Outcome of Patients With Metastatic Chromophobe Renal Cell Carcinoma Treated With SunitinibDaniel Keizman, David Sarid, Jae L Lee, et al.
The Prostate|August 24, 2019
Re-treatment with radium-223: 2-year follow-up from an international, open-label, phase 1/2 study in patients with castration-resistant prostate cancer and bone metastasesOliver Sartor, Daniel Heinrich, Neil Mariados, et al.
The Oncologist|December 7, 2013
Active smoking may negatively affect response rate, progression-free survival, and overall survival of patients with metastatic renal cell carcinoma treated with sunitinibDaniel Keizman, Maya Gottfried, Maya Ish-Shalom, et al.
Nature Medicine|June 1, 2024
Pembrolizumab for advanced urothelial carcinoma: exploratory ctDNA biomarker analyses of the KEYNOTE-361 phase 3 trialThomas Powles, Yen-Hwa Chang, Yoshiaki Yamamoto, et al.
BMC Cancer|July 25, 2024
Pembrolizumab plus either epacadostat or placebo for cisplatin-ineligible urothelial carcinoma: results from the ECHO-307/KEYNOTE-672 studyAndrea Necchi, Michiel S Van der Heijden, Dmytro Trukhin, et al.
Frontiers in Oncology|June 9, 2023
Erdafitinib treatment in metastatic urothelial carcinoma: a real-world analysisKeren Rouvinov, Eran Levanon, Avivit Peer, et al.
Nature Medicine|August 7, 2025
Adjuvant nivolumab in muscle-invasive urothelial carcinoma: exploratory biomarker analysis of the randomized phase 3 CheckMate 274 trialMatthew D Galsky, Dean F Bajorin, Yoshihiko Tomita, et al.
Urologic Oncology|October 30, 2024
Bempegaldesleukin plus nivolumab in first-line advanced/metastatic urothelial carcinoma: Results from a phase II single-arm study (PIVOT-10)Arlene O Siefker-Radtke, Robert A Huddart, Mehmet A Bilen, et al.
Pageof 5